TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: LifeVest Post-CABG Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who have undergone CABG surgery during current hospitalization~* Patients who have an ejection fraction ≤ 35% following the surgery.~* Patients who have dilated cardiomyopathy or prior myocardial infarction.~* Patients who are prescribed a wearable defibrillator following surgery.~* Patient who are at least 18 years old.~Exclusion Criteria:~* Patients who have an active ICD.~* Patients who have an active unipolar pacemaker.~* Patients having a chest circumference over 56 inches or under 26 inches.~* Patients who are unable to consent or unwilling to wear the WCD after discharge or who do not agree to be contacted at 90 days.~* Patients with a mental, visual, physical or auditory deficit that could impair their ability to properly interact with a wearable defibrillator.~* Patients participating in another clinical study with mortality as the primary endpoint.~* Patients unable to use a wearable defibrillator due to physical conditions (bandages preventing electrode contact, physical deformities preventing electrode contact, dextrocardia, etc.).~* Patients who have decided to forgo resuscitation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- wearable defibrillator use (Type: None): subjects will use a wearable defibrillator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients with clinical diagnosis of cyclic vomiting in the ED~Exclusion Criteria:~* pregnancy, allergy to any of the study medicines

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- haloperidol (Type: ACTIVE_COMPARATOR): these patients will receive 5mg IM haloperidol
- droperidol (Type: ACTIVE_COMPARATOR): these patients will receive 2.5mg IV droperidol
- ondansetron (Type: ACTIVE_COMPARATOR): these patients will receive 8mg IV ondansetron

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture for Pain Management of Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* started hemodialysis at least 3 months ago~* receiving hemodialysis 3 times a week regularly~* equilibrated Kt/V ≥ 1.2~* pain occurred at least 3 months ago~* MYMOP2 symptom 1 score ≥ 3~* willingness to participate in this study~Exclusion Criteria:~* acute/chronic liver disease~* events of life-threatening cardiovascular disease within 6 months~* events of life-threatening neurological disorder within 6 months~* current/past history of neoplasm (in past 5 years)~* hemorrhagic disorder~* drug abuse/alcoholism~* other infectious disease~* history of the use of acupuncture, moxibustion or herbs within 1 month

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Individualized acupuncture (Type: EXPERIMENTAL): None
- Routine care (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Changes of Cerebrovascular Autoregulation and Association With Cognitive Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* elective major non-cardiac/non-vascular surgery~* anticipated surgical duration \>120 minutes~* age \>= 60 years~* indication for invasive blood pressure measurement~* native German speaker~Exclusion Criteria:~* history of cerebrovascular disease~* preexisting cognitive impairment~* history or presence of neurological disease

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Adult patients (≥ 18 years)~2. Histologically or cytologically-documented NSCLC (EGFR mutation status must be known)~3. Brain metastases from NSCLC, which:~   have radiologically-progressed after WBRT or are present without prior WBRT~4. At least one radiologically-confirmed and measurable lesion (≥ 1.0 cm in the longest diameter) within14 days prior to the first dose of GRN1005 (Cycle 1, Day 1), as follows: an intra-cranial disease lesion (≥ 1.0 cm in the longest diameter) confirmed by Gd-MRI, or an extra-cranial disease lesion (≥ 1.0 cm in the longest diameter) confirmed by MRI or CT scan with contrast Prior stereotactic radiosurgery (SRS) is allowed; however, metastatic brain lesions previously treated with SRS are not allowed as target or as non-target lesions.~5. Patients must be neurologically stable, defined as being on stable doses of corticosteroids and anticonvulsants (not EIAEDs, including phenytoin, phenobarbitol, carbamazepine, fosphenytoin, primidone, oxcarbazepine) for ≥ 5 days prior to obtaining the baseline Gd-MRI of the brain and ≥ 5 days prior to first dose of GRN1005 (Cycle 1, Day 1).~6. Karnofsky Performance Score (KPS) ≥ 80%~7. Completed WBRT for intra-cranial lesions ≥ 28 days prior to first dose of GRN1005 (with the exception of local radiation therapy for palliation to extra-cranial sites, i.e., bone). All clinically significant toxicities must have resolved to ≤ NCI CTCAE v4.0 Grade 1.0.~Key Exclusion Criteria:~1. NCI CTCAE v4.0 Grade ≥ 2 neuropathy~2. CNS disease requiring immediate neurosurgical intervention (e.g., resection, shunt placement, etc.)~3. Known intra-cranial hemorrhage~4. Known leptomeningeal disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GRN1005 alone (Type: EXPERIMENTAL): GRN1005 alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: VeraFlo With Prontosan® and Wound and Fracture Healing.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years and older~* Patients who will be undergoing surgical management (including the use of NPWT therapy) of an infected lower extremity status-post open reduction and internal fixation (ORIF)~Exclusion Criteria:~* Pregnant females~* Incarcerated patients and those not able to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VeraFlo with Prontosan (Type: ACTIVE_COMPARATOR): V.A.C. VeraFlo™ Therapy, the only NPWT system with an instillation feature which allows solution to dwell in the wound for thorough contact with the wound bed. The solution being instilled is Prontosan: Unlike other antiseptics, the antimicrobial efficacy of Prontosan® is not impaired in human wound fluid, human tissue or by high loads of blood or albumin. Furthermore, Prontosan® blocks the microbial attachment to surfaces and has been shown to effectively remove biofilms in vitro and in vivo (Hubner et al 2010).
- V.A.C Ulta System (Type: ACTIVE_COMPARATOR): The V.A.C.Ulta™ Therapy System is an integrated wound therapy system that provides NPWT (negative pressure wound therapy), without instillation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults between the ages of 35-70.~* Lung transplantation listing diagnosis of pulmonary fibrosis~* Recipient of single lung transplantation within the past 60 days~Exclusion Criteria:~* History of intolerability to nintedanib (i.e. discontinued nintedanib in the pre-transplant period due to adverse drug effects)~* Liver transaminase elevation (AST or ALT \> 1.5X the upper limit of normal)~* Total bilirubin \> 1.5X the upper limit of normal~* Drugs that interfere with the metabolism or elimination of nintedanib or its metabolites - St. John's wort, carbamazepine, phenytoin, rifampin, dexamethasone, and others.~* Any history of bronchial anastomosis dehiscence or stenosis~* Bleeding risk, defined as any of the following:~  * Full-dose therapeutic anticoagulation (i.e. vitamin K antagonist, direct thrombin inhibitors, etc.)~ * History of hemorrhagic central nervous system (CNS) event within 12 months of enrollment~ * Coagulation parameters: international normalized ratio (INR) \> 2, prolongation of prothrombin time (PT) and partial thromboplastin time (PTT) by \> 1.5X the upper limit of normal at enrollment

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Nintedanib (Type: EXPERIMENTAL): Nintedanib 150 mg tablet by mouth twice daily for 24 months.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet by mouth twice daily for 24 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* With at least a 3-month documented history of bilateral dry eye~* With a score of ocular surface staining with fluorescein (OSSF) ≥ 4 and ≤ 9 on the Oxford scale~* With at least one objective sign of tear deficiency~* With Ocular Surface Disease Index (OSDI) score of ≥ 18~Exclusion Criteria:~* Refractive surgery within 12 months prior to selection~* Any other ocular surgery or ocular trauma within 6 months prior to selection~* Systemic or local use of one of the following medications: glucocorticosteroids, cyclosporine A, antibiotics, NSAIDs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Remogen (Type: EXPERIMENTAL): None
- Cationorm (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Validation of [18F]FES for Imaging of Brain Estrogen Receptors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Age \> 18 years~* For postmenopausal women: at least 1 year after menopause~* For premenopausal women: a regular menstruation~* Signed written informed consent~Exclusion Criteria:~* Use of estrogen receptor ligands, such as tamoxifen or fulvestrant~* History of ER-positive malignancies or breast cancer~* Use of any contraceptive drugs (pill, injections or implanted)~* For postmenopausal women: (history of) estrogen replacement therapy~* Pregnancy~* History of removal of the ovaries and/or the uterus~* Current systemic diseases~* Major metabolic diseases (e.g. diabetes, hyper- or hypothyroidism)~* Somatic, organic or neurological disorders~* Recent participation in a scientific research study (\<1 year) involving radiation~* Claustrophobia~* Presence of materials in the body that can be magnetized, like: pacemaker, metallic implants/prostheses, metal fragments, shunts, artificial heart valves, vascular clips, fixed hearing aid, tattoos containing metal, hair implants, artificial dentures

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Premenopausal women (Type: OTHER): healthy female subjects: premenopausal
- Postmenopausal women (Type: OTHER): healthy female subjects: postmenopausal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: a Prospective Cohort Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age of 18 years or older~* SSc diagnosis according to 1980 or 2013 ACR classification criteria~* 1 or more active DU~* Patients who start or change medical treatment for DU~* Patients who are willing to participate~Exclusion Criteria:~* Pregnancy or active breast feeding~* Patients with life expectancy \< 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Montelukast for Patients With Obstructive Sleep Apnea Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* With mild to moderate obstructive sleep apnea syndrome (apnea / hypopnea index\> 15 and \<30 events per hour)~* Little symptomatic (Epworth sleepiness score \<10)~* Polysomnography within 3 months prior to inclusion~* With a history of myocardial infarction or stroke~* Affiliation to Social Security or beneficiary of such a scheme~* Signed consent~Exclusion Criteria:~* OSAS support by PPC~* Cancer~* Chronic inflammatory disease~* Asthma previously treated with Montelukast~* Chronic infectious disease~* Epworth sleepiness scale ≥10~* Contraindication to Montelukast: Hypersensitivity to the active substance or to the excipients~* Contraindications to trinitrin: hypersensitivity to nitrates, state of shock, severe hypotension, association with sildenafil, obstructive cardiomyopathy, inferior right sided myocardial infarction with right ventricular extension, acute, except in case of signs left ventricular failure, intracranial hypertension, breastfeeding~* Treatment with phenobarbital, phenytoin, rifampicin: risk of montelukast metabolism increase and thus decrease of its effectiveness~* Persons referred in Articles L1121-5 to L1121-8 of the CSP (pregnant woman, parturient, nursing mothers, person deprived of liberty by judicial or administrative decision, person subject to a measure of legal protection, can not be included in clinical trials)~* Subject in exclusion period of another study~* Subject can not be contacted in case of emergency

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Montelukast (Type: EXPERIMENTAL): Drug :Montelukast, capsule, 10mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months
- Placebo (Type: PLACEBO_COMPARATOR): Drug: Mannitol, capsule, 350mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ST Segment Detection Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject is indicated for an ICD implantation~* AND subject must meet ONE of the following:~  * Prior acute coronary event~ * Previously underwent Percutaneous Coronary Intervention (PCI) or stent procedure~ * Multivessel disease~ * Positive stress test completed with evidence of ischemic heart disease, as determined by physician, and no subsequent successful revascularization~Exclusion Criteria:~* Subject is currently dependent on ventricular pacing~* Subject has Left Bundle Brunch Block (LBBB) and/or wide QRS~* Subject has chronic Atrial Fibrillation (AF)~* Subject has dementia~* Subject is indicated for a single chamber device~* Subject requires a right sided or abdominal ICD implant~* Subject is pregnant or in fertile age without secure birth control~* Subject has New York Heart Association (NYHA) class IV or refractory heart failure~* Subject is not expected to survive greater than 12 months~* Subject is participating in other confounding research studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of NMES on Muscle Function of Patients With FSHD: a Double-blind Randomized Controled Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Molecular and/or clinical diagnosis for FSHD~* Vignos scale ≤ 5: Able to walk without help~* Clinically characterized by quadriceps muscle weakness but with a maximal voluntary contraction (MVC) between 8 and 16 Kg~* Follow as part of their usual care in the Clinical Physiology Department of the University Hospital of Montpellier~* Free and informed consent of the patient~* Patient affiliated or beneficiary of a social security system~Exclusion Criteria:~* Patient with co-morbidity:pathologies heart, pathologies respiratory, metabolic and endocrine -pathologies, pathologies cancer.~* Patients treated with drugs could cause muscle side effects or interfere with muscle metabolism.~* Lesions or skin inflammation at the thighs that can prevent the application of NMES~* Claustrophobic subject~* Carrier of intracranial vascular clip, cardiac pacemaker, neurostimulator, cochlear implant, or intraocular metallic foreign~* Pregnant or nursing women~* Vulnerable Persons and protected Major or unable to consent~* Patient in exclusion period relative over another protocol, or for which the annual amount of maximum compensation of € 4,500 has been reached

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: SHAM_COMPARATOR): The current intensity is generally defined between the sensory and motor threshold (patients feel the power but no visible muscle contraction will be obtained).
- Active NMES group (Type: ACTIVE_COMPARATOR): Tthe current intensity must always meet and exceed the motor threshold (patients feel the current and quadriceps muscle will contract a visible and quantifiable if possible).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antepartum Betamethasone Treatment for Prevention of Respiratory Distress in Infants Born by Elective Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women \>/= 34 weeks gestation scheduled to undergo operative delivery within 48-72 hours after study enrollment~Exclusion Criteria:~* Known contraindication to the use of betamethasone in the mother~* Known lethal or non-lethal congenital anomaly diagnosed antenatally~* Spontaneous labor~* Premature rupture of membranes

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Betamethasone (Type: EXPERIMENTAL): Betamethasone injection
- Placebo (Type: PLACEBO_COMPARATOR): Placebo injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues